Juvéderm Volbella XC approved for use in lips and perioral rhytids

Allergan has received approval from the US Food and Drug Administration (FDA) to market Juvéderm Volbella XC, for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as perioral lines, in adults over the age of 21.

In clinical trials, the product was found to effectively increase lip fullness and soften the appearance of lines around the mouth in a majority of subjects through one year.

“Many of my patients are very bothered by the lines that can appear around the lips, known as perioral rhytids. Additionally, when seeking lip augmentation, patients want a smooth, result that is not drastic”, said Dr David E Bank, clinical trial investigator and founder of The Center for Dermatology, Cosmetic & Laser Surgery. “Juvéderm Volbella XC adds fullness to the lips and softens the appearance of the lines around the lips.”

Juvéderm Volbella XC is formulated with Vycross, a proprietary filler technology from Allergan, which yields smooth products that have been engineered to address specific patient concerns such as lip fullness, age-related volume loss in the cheek area, or perioral rhytids.